600812.SS
600812.SS
CNE000000D16
NORTH CHINA PHARMACEUTICAL CO
Loading chart...

Company Profile

North China Pharmaceutical Company.Ltd engages in the research and development, production, and sale of pharmaceutical products in China and internationally. The company primarily offers anti-infective, biotechnology, and cardiovascular cerebrovascular drugs; and immunomodulators, vitamins, and health products. It also provides chemical, biological, agricultural, and biopharmaceuticals and veterinary drugs. It serves pharmaceutical distributors, agents, hospitals, chain pharmacies, and end-user clinics. North China Pharmaceutical Company.Ltd was founded in 1992 and is headquartered in Shijiazhuang, China.

Related stocks

600993.SS
600993.SS • China
MAYINGLONG PHARMACEUTICAL GP CO
22.95 CNY
1.48B USD 1Y -15%
600572.SS
600572.SS • China
ZHEJIANG CONBA PHARMACEUTICAL C
4.41 CNY
1.68B USD 1Y +0.5%
002099.SZ
002099.SZ • China
HISOAR
6.32 CNY
1.53B USD 1Y +8%
600211.SS
600211.SS • China
TIBET RHODIOLA PHARMACEUTICAL H
36.78 CNY
1.77B USD 1Y -22.9%
002332.SZ
002332.SZ • China
XJZY
8.76 CNY
1.3B USD 1Y -11.2%
600789.SS
600789.SS • China
SHANDONG LUKANG PHARMACEUTICAL
8.28 CNY
1.29B USD 1Y -15.3%
600420.SS
600420.SS • China
SHANGHAI SHYNDEC PHARMACEUTICAL
8.51 CNY
1.71B USD 1Y -20.2%
300026.SZ
300026.SZ • China
CHASE SUN PHARM.
3.32 CNY
1.49B USD 1Y -10.8%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
36.4% p.a.
Max Drawdown (5Y)
-69.3%
Sharpe Ratio (5Y)
-0.25
Beta Factor
0.20
Size Class
Large Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
🔴 High valuation risk: Avg P/E of 86.1 (Elevated multiple compression risk)
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (36.4% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -78.9% in the extended horizon.
ende